Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Lexicon Pharmaceuticals reports Q3 progress amidst financial challenges and opportunities

Lexicon Pharmaceuticals showcased progress in key development programs and strategic partnerships in Q3 2024.
Despite financial challenges, the company's operational strengths and focus on growth opportunities are notable.
Navigating uncertainties around ZYNQUISTA and competition in the market are key challenges ahead.
Overall, the company's performance, strengths, challenges, and opportunities shape its strategic outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q4 results. Quarterly Results • Earnings per share came in at a loss of $0.48, which beat the estimate calling for a loss of $0.77.

Lexicon Pharmaceuticals: Q4 Earnings Insights

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2019 Results - Earnings Call Transcript

Lexicon (LXRX) delivered earnings and revenue surprises of 36.84% and -17.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates

THE WOODLANDS, Texas, Jan.  24, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today real-world data on XERMELO’s ®  (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January 23-25, San Francisco, CA). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.

Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome

Axsome Therapeutics

Galapagos

These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q1 2020.

Top Biotech Stocks for Q1 2020

Shares of Lexicon Pharmaceuticals Inc. are down 5% in premarket trading on Friday after the biopharmaceutical company said that its experimental Type 2 diabetes treatment met its primary and secondary endpoints in a late-stage clinical trial.

Lexicon shares fall on diabetes study data

THE WOODLANDS, Texas, Dec.  20, 2019  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. The topline results are as follows:

Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

Investors need to pay close attention to Lexicon (LXRX) stock based on the movements in the options market lately.

Implied Volatility Surging for Lexicon (LXRX) Stock Options

THE WOODLANDS, Texas, Dec.  05, 2019  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in development for the treatment of neuropathic pain.

Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

THE WOODLANDS, Texas, Dec.  03, 2019  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2 clinical study of telotristat ethyl in patients with biliary tract cancer. Telotristat ethyl is a novel, oral tryptophan hydroxylase (TPH) inhibitor approved as XERMELO® for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy alone.

Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

Ollie's Bargain Outlet Hlds

Roku

Find out how an unexpected tragedy hit one of these stocks.

Why Roku, Ollie's Bargain Outlet Holdings, and Lexicon Pharmaceuticals Slumped Today

The FDA rebuffed the company's appeal for a failed new drug application. What happens now?

Here's Why Lexicon Pharmaceuticals Is Tumbling Today

Lexicon Pharmaceuticals, Inc. shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin.

Why Lexicon Pharma Shares Are Moving Lower

Lexicon Pharmaceuticals Inc. shares LXRX, -0.84% slid 15% in premarket trade Monday, after the company said the U.S.

Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drug

Despite doubts over its lead drug candidate and the loss of a major partner, the company is forging ahead.

Is Lexicon Pharmaceuticals a Buy?

THE WOODLANDS, Texas, Nov.  14, 2019  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

Lexicon Pharmaceuticals to  Present at Upcoming Investor Conference

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?

Lexicon Pharmaceuticals, Inc (LXRX) CEO Lonnel Coats on Q3 2019 Results - Earnings Call Transcript

Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth

THE WOODLANDS, Texas, Oct.  02, 2019  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO ®  (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium (NANETS; October 3-5, Boston, MA).

Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium

Hovnanian Enterprises

Contango Oil & Gas

111 Inc - ADR

We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.

Small Caps Win in September: 5 Best ETFs & Stocks

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock?

Lexicon (LXRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Lexicon (LXRX) Catches Eye: Stock Jumps 7.3%

Investors are jumping in ahead of a data presentation tomorrow.

News for Lexicon Pharmaceuticals Stock (LXRX)